BrainStorm Therapeutics (BST) is a biotech startup dedicated to addressing the urgent global brain disease crisis. We are developing an innovative AI-powered human brain organoid platform to develop groundbreaking therapies that halt, prevent, or reverse synaptic network dysfunction and neurodegeneration. By applying a precision medicine approach focused on human genetics, brain organoids, clinically translatable screening endpoints, advanced data analytics, and network medicine, we are establishing a robust artificial intelligence system that evolves through iterative outcomes of functional genomic and high-throughput drug perturbations of patient-derived brain organoids to guide target identification, patient stratification, target modulation, and therapeutic focus. BST is led by an experienced team of CNS drug developers, brain organoid pioneers, neuroscientists, and data scientists who have collectively advanced 12 programs into the clinic for neurological disorders.